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We evaluated antimicrobial exposure, discharge diag-
noses, or both to identify surgical site infections (SSI). This
retrospective cohort study in 13 hospitals involved weight-
ed, random samples of records from 8,739 coronary artery
bypass graft (CABG) procedures, 7,399 cesarean deliver-
ies, and 6,175 breast procedures. We compared routine
surveillance to detection through inpatient antimicrobial
exposure (>9 days for CABG, >2 days for cesareans, and
>6 days for breast procedures), discharge diagnoses, or
both. Together, all methods identified SSI after 7.4% of
CABG, 5.0% of cesareans, and 2.0% of breast procedures.
Antimicrobial exposure had the highest sensitivity,
88%–91%, compared with routine surveillance, 38%–64%.
Diagnosis codes improved sensitivity of detection of antimi-
crobial exposure after cesareans. Record review confirmed
SSI after 31% to 38% of procedures that met antimicrobial
surveillance criteria. Sufficient antimicrobial exposure days,
together with diagnosis codes for cesareans, identified
more postoperative SSI than routine surveillance methods.
This screening method was efficient, readily standardized,
and suitable for most hospitals. 
Preventing healthcare-associated infections, includingsurgical site infections (SSI), is an integral part of the
national patient safety agenda developed in response to the
Institute of Medicine’s report, To Err is Human: Building a
Safer Health System (1). Although nearly all hospitals
monitor their SSI rates, no generally accepted active sur-
veillance method is both reproducible and widely used.
Fewer than 10% of hospitals participate in the Centers for
Disease Control and Prevention’s (CDC) National
Nosocomial Infection Surveillance System (NNIS). Many
hospitals use surveillance systems based more or less
closely on NNIS; most of these systems are labor-intensive
and their sensitivity is typically unknown. 
We therefore studied the ability of exposure to antimi-
crobial drugs and coded discharge diagnoses to identify
SSI after three common procedures: coronary artery
bypass graft (CABG) procedures, cesarean delivery, and
breast procedures. We chose these measures because prior
work suggested their usefulness (2,3), nearly all hospitals
collect this information as part of routine patient care, and
many hospitals store this information electronically. 
Methods
We conducted this study in two phases in 13 hospitals
affiliated with the seven CDC epicenters. Phase 1 involved
seven teaching and community hospitals in eastern
Massachusetts. Phase 2 involved hospitals in seven states.
The study design was similar for each of the procedures,
although the antimicrobial intervals required to trigger
record review were procedure-specific and based on earli-
er work (2,3). We describe the methods in detail for CABG
procedures and then provide additional information for
cesarean delivery and breast procedures. The number of
hospitals assessing the three procedures differed because
of different practice patterns. 
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CABG Procedures 
Phase 1–Eastern Massachusetts Epicenter
We studied consecutive CABG procedures performed
from April 1, 1998, through January 31, 1999, in four
hospitals. Qualifying International Classification of
Diseases 9th Revision Clinical Modification (ICD-9-CM)
procedure codes are listed in the online Appendix
(http://www.cdc.gov/ncidod/eid/vol10no11/04-0572_
app.htm). Infection control professionals performed
prospective inpatient SSI surveillance, typically once or
twice per week, using the NNIS definitions (4). The surgi-
cal sites usually were not observed directly by the infection
control professionals. We included SSI detected during the
initial hospital admission for the CABG procedure or any
readmission to the same hospital that occurred within 60
days of the operative procedure. Weeks or months later, the
hospitals’ information systems and medical records were
used to obtain information about antimicrobial drug expo-
sure and discharge diagnoses. 
Discharge Diagnosis Codes Screening 
and Antimicrobial Exposure Screening
We identified patients with ICD-9-CM discharge diag-
nosis codes that suggest SSI (see online Appendix at
h t tp : / /www.cdc .gov /nc idod /e id /vo l10no11 /04-
0572_app.htm) from their initial hospitalization or read-
mission to the same hospital within 60 days of the
operative procedure. 
We identified patients for whom >9 days elapsed from
the first to the last postoperative dates on which they
received parenteral or oral antimicrobial drugs (i.e., an
antimicrobial interval of >9 days), based on the results of
prior work (2). The first postoperative day was ignored
because antimicrobial prophylaxis was typically given at
that time. Patients did not need to receive antimicrobial
agents on each day or the same agent throughout the inter-
val. For instance, a patient could meet the 9-day criterion
by receiving cefazolin on the second postoperative day, no
antimicrobial drug on postoperative days 3 through 10,
then receive an oral quinolone on postoperative day 11.
This definition simplified data collection and is nearly as
efficient as a measure that required the same antimicrobial
drug to be administered continuously during the interval
(2). We also identified patients who received any oral or
parenteral antimicrobial drug during a readmission to the
same hospital within 60 days of the operative procedure.
Antiviral drugs and antifungal agents were excluded. 
Identification through Antimicrobial Exposure
or ICD-9-CM Code and Interreviewer Reliability
Infection control professionals reviewed the medical
records of all patients who met either the antimicrobial
drug exposure or ICD-9-CM diagnosis code criteria but
who had not been classified as infected during prospective
NNIS-based surveillance. The infection control profes-
sionals used NNIS criteria to classify the patients’ infec-
tion status. An NNIS-trained infection control professional
who was not affiliated with any of the participating hospi-
tals also reviewed the medical records of all patients who
were classified as not having an SSI by routine surveil-
lance but who met diagnosis code, antimicrobial drug
exposure screening criteria, or both.
Analysis and Statistical Methods
Incidence rates of SSI, the sensitivity and the positive
predictive value of original prospective surveillance,
antimicrobial drug exposure screening, diagnosis
code–screening, and combinations of these were deter-
mined against the standard criterion created by combining
the SSI detected prospectively during routine surveillance
and the SSI identified retrospectively when medical records
were reassessed. We defined the positive predictive value
of routine prospective surveillance to be 100%. Logistic
regression was used to evaluate whether diagnosis codes
and antimicrobial drug exposure were performed homoge-
nously across the participating hospitals. The κ statistic was
used to assess agreement in SSI classification between hos-
pital-based infection control professionals and the external
reviewer (SAS software, v. 8, SAS Institute, Cary, NC)
Phase 2–All Epicenters 
One hospital participated from each of the six epicen-
ters that performed CABG procedures. One hospital had
also participated in phase 1. The study population includ-
ed consecutive CABG procedures performed from July 1,
1999, through June 30, 2001, in the six hospitals. 
The methods described for phase 1 were also used for
phase 2, except that research personnel retrospectively
reviewed the medical records of all patients who had been
classified by routine surveillance as having SSI. In addi-
tion, research personnel also reviewed the medical records
of a random sample of 200 patients who underwent CABG
procedures at each hospital to identify patients with ICD-
9-CM diagnosis codes suggestive of SSI, to extract antimi-
crobial drug exposure data, and to retrospectively reassess
each patient for the presence of an SSI. 
The total number of SSI was estimated by multiplying
the SSI rate identified by medical record review in the ran-
dom sample of patients not known to have SSI based on
routine surveillance by the number of patients in the entire
group who were not known to have SSI. This estimate was
added to the number of SSI identified through routine sur-
veillance to estimate an adjusted SSI rate for each hospital.
The sensitivity and positive predictive value of original
prospective surveillance, screening by antimicrobial drug
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 11, November 2004 1925
Identifying Postoperative Infections, Inpatients
intervals, screening by diagnosis codes, and combinations
of these were estimated by using the known sampling frac-
tions to extrapolate to the source population. Binomial
confidence intervals (CI) were calculated for SSI rates on
the basis of the random sample and extrapolated to the
source population (Stata software, v. 8.2, Stata
Corporation, College Station, TX). Logistic regression was
used to evaluate whether screening for SSI by diagnosis
code and antimicrobial drug exposure was performed
homogenously across the participating hospitals (SAS
software, version 8, SAS Institute, Cary, NC).
Cesarean Deliveries 
Phase 1–Eastern Massachusetts Epicenter
We studied consecutive cesarean deliveries performed
from April 1, 1998, through January 31, 1999, in five hos-
pitals. Qualifying procedure codes are listed in the online
Appendix (http://www.cdc.gov/ncidod/eid/vol10no11/04-
0572_app.htm). Each participating hospital performed
routine inpatient SSI surveillance. We identified patients
assigned an ICD-9-CM diagnosis code that suggested SSI
(online Appendix), who met antimicrobial drug exposure
criteria during the initial hospital admission or any read-
mission to the same hospital within 60 days of the opera-
tive procedure, or both. We used an antimicrobial drug
interval of >2 days for cesarean deliveries. Medical record
review and analysis were performed as described. 
Phase 2–All Epicenters
One hospital from each of four epicenters evaluated
cesarean deliveries occurring from July 1, 1999, through
June 30, 2001. Two hospitals used the methods described.
In two other hospitals that had not performed routine
prospective inpatient surveillance for SSI, research per-
sonnel retrospectively reviewed the medical records of all
patients who met either ICD-9-CM diagnosis code or
antimicrobial exposure criteria, plus records from a ran-
dom sample of 200 other patients. 
The total number of SSI was estimated as described.
For the hospitals without routine surveillance, the total
number of SSI was estimated by multiplying the SSI rate
in the random sample by the number of patients in the
entire group who did not meet diagnosis code or antimi-
crobial exposure criteria. This estimate was added to the
number of SSI identified through medical record review of
patients who met diagnosis code or antimicrobial drug
exposure criteria to calculate an estimated adjusted SSI
rate for each hospital. 
Breast Procedures
Phase 1–Eastern Massachusetts Epicenter
We studied consecutive breast procedures performed
from April 1, 1998, through January 31, 1999, in seven
hospitals (see procedure codes in the online Appendix).
Routine inpatient SSI surveillance, ICD-9-CM diagnosis
code (online Appendix) and antimicrobial drug exposure
screening, and medical record review were performed as
described. We used an antimicrobial interval of >6 days for
breast procedures. 
Phase 2–All Epicenters
One hospital from each of five Epicenters participated.
Three of the five hospitals did not perform routine
prospective inpatient surveillance for SSI after breast pro-
cedures. Methods for screening, sampling, estimating SSI
rates, sensitivities, and positive predictive value were as
described for cesarean deliveries.
Results 
A total of 8,739 CABG procedures, 7,399 caesarean
deliveries, and 6,175 breast procedures were assessed
(Table 1). In addition to routine prospective surveillance as
described, 189–451 charts per procedure type were
reviewed at each hospital. Hospital-specific results are
shown in the online Appendix (http://www.cdc.gov/nci-
dod/eid/vol10no11/04-0572_app.htm). 
CABG Procedures
Phase 1
The overall SSI rate based on confirmed infections
detected by any of the three methods was 6.3% (Table 2).
1926 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 11, November 2004
RESEARCH
The sensitivities of routine prospective surveillance (79%)
and antimicrobial drug exposure screening (80%) were
essentially equal and both substantially exceeded that of
ICD-9-CM diagnoses codes (61%) (Table 3). The positive
predictive value of antimicrobial drug exposure (33%) was
considerably lower than that for surveillance based on
diagnosis codes (86%), which reflected the fact that 15%
of patients met the antimicrobial drug exposure criteria
compared with 4.5% of those who were assigned the
screening diagnosis codes. The patients who met either the
antimicrobial drug exposure or diagnosis code–screening
criteria overlapped substantially, which resulted in the
joint measure’s having performance characteristics similar
to that of antimicrobial drug exposure screening alone. 
The SSI classification assigned by hospital-based and
external reviewers agreed for 107 (82%) of 130 proce-
dures, with an overall κ coefficient of 0.66 (95% CI 0.53,
0.79). κ coefficients did not vary significantly across hos-
pitals (p = 0.11).
Phase 2
The overall rate of confirmed SSI based on the combi-
nation of methods was 7.7% (Table 2); approximately one
third of these were deep sternal SSI (SSI rates of 2.2% for
deep sternal, 2.5% for superficial sternal, 3.1% for super-
ficial donor site, and 0.2% for deep donor site SSI). In con-
trast to phase 1, antimicrobial drug exposure screening
(>9 days) identified substantially more infections (sensi-
tivity 91%) than routine surveillance (59%), which per-
formed slightly better than coded discharge diagnoses
(54%) (Table 3). The sensitivity did not vary meaningfully
for different SSI types. The combination of a >9-day
antimicrobial interval and discharge diagnoses identified
93% of SSI. The overall positive predictive values of
antimicrobial drug screening, diagnosis code screening,
and the combination of both were similar to those observed
in phase 1, with higher values for diagnosis codes. The
proportions of patients meeting the three screening criteria
were also similar to the values observed in phase 1
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 11, November 2004 1927
Identifying Postoperative Infections, Inpatients
(Table 4). A more liberal antimicrobial interval of >7 days
negligibly increased sensitivity from 91% to 93%, reduced
the positive predictive value to 30%, and increased the
proportion of patients who met the criteria to 23% (online
Appendix Table 4 available at http://www.cdc.gov/nci-
dod/eid/ vol10no11/ 04-0572_app.htm). We observed no
significant heterogeneity in the performance of screening
by antimicrobial threshold to detect SSI among the six hos-
pitals (p = 0.9). 
Cesarean Delivery Surveillance
Phase 1
The overall rate of confirmed SSI was 4.1%, based on
the combination of methods (Table 2). An antimicrobial
interval of >2 days identified 90% of infections, compared
with diagnosis codes alone (48%) and routine surveillance
(39%) (Table 3). Approximately 9% of patients met the
antimicrobial drug exposure criterion, and 3.2% had one of
the discharge diagnoses of interest (Table 3). The combi-
nation of antimicrobial drug exposure and diagnosis codes
increased sensitivity slightly (96%) and was similar to
antimicrobial drug exposure alone in predictive value and
percentage of patients who met the criterion. 
Phase 2
The overall infection rate was 5.5% (Table 2). The per-
formance of the surveillance measures was similar to their
performance in phase 1, in that an antimicrobial interval of
>2 days identified substantially more infections (84%)
than routine surveillance (38%, for the two hospitals that
performed routine surveillance). Results of routine surveil-
lance were comparable to those of antimicrobial drug
exposure for deep incisional SSI (SSI rate of 0.3% for
each), with superficial incisional SSI (0.3% vs. 1.3%) and
endometritis (1.0% vs 2.6%), which accounted for the
lower sensitivity of routine surveillance. In this phase,
diagnosis codes (84% sensitivity) performed substantially
better than routine surveillance and nearly as well as
antimicrobial exposure. The positive predictive value to
detect SSI was highest for diagnosis code–based screening
(67%), and it was 37% for screening by antimicrobial drug
exposure. The combination of antimicrobial exposure,
diagnosis code–screening, or both improved sensitivity to
97% and had a positive predictive value similar to that of
antimicrobial drug exposure alone.
As observed for CABG procedures, the proportions of
patients who met screening criteria were similar for
antimicrobial drug exposure alone (12.7%) and the combi-
nation of antimicrobial exposure and diagnosis codes
(14.1%). A smaller proportion (6.4%) met only diagnosis
code–screening criteria. 
Breast Surgery Surveillance
Phase I
The overall confirmed SSI rate was 0.9%, based on the
combination of all three methods (Table 2). Routine sur-
veillance and antimicrobial drug exposure screening iden-
tified 71% of SSI (Table 3), compared with 50% for
diagnosis codes. The combination of antimicrobial drug
exposure and diagnosis codes identified 79%. The positive
predictive value to detect SSI was highest for diagnosis
code–based screening (58%), and was 19% and 20%,
respectively, for screening by antimicrobial exposure and
screening by a combination of antimicrobial drug exposure
and diagnosis codes. The percentages of patients who met
antimicrobial exposure criteria, diagnosis code criteria,
and a combination are listed in Table 4. 
Phase 2
The overall SSI rate, based on all three methods, was
higher (2.2%) in this phase. Antimicrobial drug exposure
was the most sensitive measure; it identified 94% of infec-
tions, compared with 70% for diagnosis codes and 33% for
routine surveillance (two hospitals’ data). The sensitivity
of routine surveillance was similar for both deep and
superficial infections. 
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The positive predictive value for detecting SSI was
highest for diagnosis codes (79%); the positive predictive
value was 33% for antimicrobial exposure alone and for
the combination of antimicrobial drug exposure and
diagnosis codes. The proportions of patients who met
screening criteria were similar with antimicrobial drug
exposure alone and the combination of antimicrobial expo-
sure and diagnosis codes (6.7% and 6.8%, respectively),
with a smaller proportion (2.0%) who met only diagnosis
code–screening criteria. 
Discussion 
Many hospitals do not perform active SSI surveillance
because it requires substantial resources. When hospitals do
perform surveillance, our experience indicates that they
often miss a substantial portion of infections. In the current
study, many infections were missed after cesarean delivery
and breast surgery, possibly because brief postoperative
hospitalizations and infrequent readmissions for infection
limited the efficiency of routine surveillance. The typical
absence of microbiologic culture data associated with
postcesarean endometritis may have also compromised the
sensitivity of routine SSI surveillance after cesarean deliv-
ery. Furthermore, hospitals often cannot meaningfully com-
pare their results with those from other hospitals because
surveillance methods are not standardized. In contrast, sur-
veillance based on antimicrobial drug exposure and diagno-
sis codes is objective and uses information that is collected
routinely and is often available electronically. These factors
may facilitate surveillance that performs uniformly over
time and between institutions. We believe this method is
likely to be widely applicable because the hospitals we stud-
ied had well-developed, independent surveillance programs
and used a variety of different information technologies, yet
all substantially improved their detection of SSI. 
Overall, inpatient antimicrobial drug exposure was the
best single measure for identifying SSI. We improved this
measure’s specificity by ignoring antimicrobial drugs
administered on the operative and first postoperative days,
when many patients receive perioperative antibiotic pro-
phylaxis, and by omitting the large number of patients who
received brief courses of antimicrobial drugs for other rea-
sons. Even so, most patients identified by this method did
not have conditions that met the CDC’s SSI definitions. We
previously observed that many of these patients without SSI
are either “near misses,” that is, they had signs and symp-
toms that prompted physicians to treat them as if they had
an infection, or they had healthcare-associated infections at
other sites (2). Therefore, above-threshold antimicrobial
drug exposure can be a useful marker for clinically impor-
tant postoperative illness that does not meet formal criteria
for postoperative infection or for which documenting the
medical record is insufficient to confirm a diagnosis.
In institutions such as the teaching and community hos-
pitals in this study, infection control professionals will
need to review from 4% to 20% of medical records to
determine the SSI status for each patient who meets
antimicrobial drug exposure or diagnosis code criteria, a
percentage that is substantially lower than that required by
routine surveillance. Moreover, confirming the status of
each patient may not be necessary when the fraction of
patients who meet the antimicrobial drug exposure criteri-
on is within a stable range. Infection control professionals
could reserve such assessments for instances when the ele-
vation of this fraction above a specified threshold suggests
the need for additional investigation. 
The addition of diagnosis codes to antimicrobial
drug–based surveillance improved sensitivity by 2% to
10%. Diagnosis codes improved screening for SSI after
cesarean deliveries most markedly. In general, added sen-
sitivity is likely not worth the extra effort currently
required in most institutions to work with two different
data sources. Screening for more codes might increase the
sensitivity of this measure. The incremental value added
by other types of information, such as microbiologic data,
which have been studied by others (5,6), is unknown.
Including such information, however, would add complex-
ity to the process of acquiring and evaluating data. When
additional automated data sources become widely avail-
able, the contribution they can make should be determined. 
This study has several limitations. First, we may have
missed some infections because we did not review the med-
ical records from all patients or because the medical records
had insufficient documentation. Second, before this sur-
veillance method can be extended beyond these three sur-
gical procedures, specific antimicrobial intervals will need
to be evaluated for other procedures. Thus, additional stud-
ies are needed to assess the usefulness of this approach for
other surgical procedures. Third, and perhaps most impor-
tantly, our studies did not address postdischarge surveil-
lance for SSI, except when patients were readmitted to the
same hospital. Therefore, assessment of inpatient antimi-
crobial drug exposure is only useful as a substitute or
enhancement for traditional methods for detecting SSI
among inpatients. The important problem of detecting post-
discharge infections in patients who are not readmitted to
the same hospital must be addressed through other means
(e.g., through the use of automated claims data) (7).
To reduce the number of SSI, we need to better under-
stand their occurrence in all hospitals that perform opera-
tions, which is not possible by using current surveillance
methods. One way to perform standardized surveillance in
all hospitals would be to use relatively simple, broad-based
surveillance among inpatients by monitoring antimicrobial
drug exposure, together with more intensive surveillance
of hospitals that appear to have high infection rates not
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explained by the difference in underlying patient risks for
infection. Confirming a high case-mix adjusted infection
rate would prompt evaluation of opportunities to improve
policies, procedures, and training for personnel. Our stud-
ies indicate that monitoring inpatient antimicrobial drug
exposure, possibly in combination with diagnosis codes
for certain procedures, identifies more infections, requires
fewer resources, and may be more easily standardized than
conventional surveillance. These methods might replace
conventional surveillance in some situations or, at a mini-
mum, be used to focus valuable surveillance resources on
patients most likely to have SSI.
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